Journal of International Obstetrics and Gynecology ›› 2017, Vol. 44 ›› Issue (4): 396-398.
Previous Articles Next Articles
ZHANG Yang, DONG Tian-rui, NI Jin-hong
Received:
Revised:
Published:
Online:
Abstract: Objective: To discuss different concentrations of salidroside on inhibition of cervical cancer HeLa cells proliferation and its mechanism. Methods: Concentration of 5, 50, 500 μg/mL salidroside cultured in vitro after 24 h, were determined by MTT method to observe for growth inhibition, flow cytometry technique and Hoechst staining were used to observe apoptosis of HeLa cells, and colorimetry was used to detect the expression of apoptosis related factor Caspase-3 and Caspase-9. Results: The survival rate of different dose of salidroside were (82.00±3.65) %, (59.33±2.39)%, and (54.00±2.61) %, the difference was statistically significant (P<0.05) compared with negative control group (97.33±3.45) %; Flow cytometry technology results showed that the percentage of apoptosis cells in low, medium and high concentration salidroside group were (20.53±5.76) %, (32.43±3.53) % and (42.40±3.39) % respectively, the difference was statistically significant (P<0.05) compared with negative control group (1.33±0.95) %; Hoechst33258 nuclear staining method showed that salidroside could increase the number of apoptosis cells, in addition, salidroside could also increase expression level of Caspase-3 and Caspase-9. Conclusions: Salidroside inhibited cervical cancer HeLa proliferation by enhancing the expression of Caspase-3 and Caspase-9, inducing its apoptosis, which indicated that salidroside may play a certain role in the treatment of cervical cancer.
Key words: Salidroside, Hela cells, Apoptosis, Caspase 3, Caspase 9
ZHANG Yang, DONG Tian-rui, NI Jin-hong. The Study of Salidroside on Inhibition of Cervical Cancer HeLa Cells Proliferation[J]. Journal of International Obstetrics and Gynecology, 2017, 44(4): 396-398.
/ Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.gjfckx.ac.cn/EN/
https://www.gjfckx.ac.cn/EN/Y2017/V44/I4/396